Replay available

Biovica International AB (publ) (BIOVIC_B) Q1 2027 Earnings Call

Biovica International AB (publ) (STO: BIOVIC_B) Q1 2027 earnings conference call, held 2026-09-10. Replay captured from the company's public earnings webcast.

Thu, September 10, 2026 at 9:00 AMendedReplay
Biovica International AB (publ) (BIOVIC_B) Q1 2027 Earnings Call

Investor webinar replay

Meeting Overview The meeting was a Q1 earnings call for BioVika, led by CEO Thijs Kipling and CFO Anders Morén. They discussed the company's financial performance, commercial traction, and future growth opportunities, particularly in the field of hormone receptor positive metastatic breast cancer and pharma services. Key Discussion Points - Introduction of BioVika and its FDA-cleared blood test for breast cancer. - Financial highlights for Q1, including a 56% increase in net sales year-over-year. - Overview of commercial traction in the US, with significant growth in test volumes and account retention. - Future plans for clinical trials and expansion into early breast cancer. - Discussion of the pharma business and its revenue potential, including ongoing collaborations and market opportunities. - Leadership changes, including the appointment of a new CFO. Decisions Made - No explicit decisions recorded. Action Items & Next Steps - [Unassigned] : Publish the presentation with append...

Latest press releases

Companies on this event

Featured Presenters

Anders Morén

CFO

Tijs Kipling

CEO

Replay transcript excerpt

Speaker 1: Hello and welcome to this live Q with Bivika. Speaker 1: 1st off Speaker 1: we will have a presentation Speaker 1: from Bivika and from Thijs Kipling and Speaker 1: Anders Morén Speaker 1: and after that we will have a Q&A session and please feel free to send in your questions through our webpage. Speaker 1: So please, Bjovika, go ahead and do your presentation. Speaker 2: Thank you very much. Speaker 2: So, Speaker 2: Good morning here from San Diego in the US and welcome to BioVika's Q1 2026-2027 Speaker 2: earnings call. Speaker 2: My name is Thijs Kiepling, I'm the CEO of BioVika and I'm joined today by our CFO Speaker 2: Anders Moraen. Speaker 2: Before we get into the results, Speaker 2: slide 2 contains our standard forward-looking statements disclaimer and I'd encourage you to read it at your convenience. Speaker 2: Today's Speaker 2: presenters are beyond myself, also our CFO Anders Moraen, who will take part in the Q&A session later Speaker 2: in the presentation. Speaker 2: We will begin with Speaker 2: a brief introduction to BioVika Speaker 2: followed by our Q1 highlights, a financial update, Speaker 2: and then we close with a few summary remarks Speaker 2: before opening Speaker 2: the call for Q&A. Speaker 2: We welcome you, as mentioned, Speaker 2: to submit written questions through the chat. These will be answered Speaker 2: in writing and appended to the end of the presentation which will be published on BioVeka. Speaker 2: And joining us today, as mentioned, is the analyst Fredrik Thordt from RedEye. Speaker 2: In the next few slides, I'd like to introduce Buvika and highlight Speaker 2: several aspects of the company that I believe Speaker 2: make for a particular Speaker 2: compelling investment case. Speaker 2: Is our FDA Speaker 2...

More from Biovica International Ab Class B